
Opinion|Videos|February 7, 2025
Clinical Perspectives: Question to Start Asking Is Who Not to Give Quadruplet CD38-Containing Regimens in Transplant-Eligible NDMM
Panelists discuss how the paradigm in transplant-eligible newly diagnosed multiple myeloma (NDMM) has shifted to considering which patients should not receive quadruplet CD38-containing regimens rather than who should, given the compelling efficacy data supporting this approach.
Episodes in this series






































